Dainippon Sumitomo Pharma Co., Ltd. Announces Launch of “Replagal(R) 3.5 mg” for Anderson-Fabry Disease

February 27, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Tokyo, Feb 15, 2007 (JCN Newswire) - Dainippon Sumitomo Pharma Co., Ltd. (DSP) announces the upcoming launch on the 15 of February of "Replagal(R) 3.5 mg" (nonproprietary name: Agalsidase Alfa (Genetic Recombination)) hereafter, Replagal.

Twitter
LinkedIn
Facebook
Email
Print

Asia